Splenic marginal zone lymphoma historical perspective

Jump to navigation Jump to search

Splenic marginal zone lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Splenic marginal zone lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Splenic marginal zone lymphoma historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Splenic marginal zone lymphoma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Splenic marginal zone lymphoma historical perspective

CDC on Splenic marginal zone lymphoma historical perspective

Splenic marginal zone lymphoma historical perspective in the news

Blogs on Splenic marginal zone lymphoma historical perspective

Directions to Hospitals Treating Splenic marginal zone lymphoma

Risk calculators and risk factors for Splenic marginal zone lymphoma historical perspective

Overview

The term splenic marginal zone lymphoma (SMZL) was first used by C. Schmid in 1992 and described as separate entity from marginal zone lymphoma in the World Health Organization classification of lymphoid neoplasms in 2001.

Historical Perspective

References

  1. Schmid C, Kirkham N, Diss T, Isaacson PG (May 1992). "Splenic marginal zone cell lymphoma". Am. J. Surg. Pathol. 16 (5): 455–66. PMID 1599024.
  2. Chan JK (December 2001). "The new World Health Organization classification of lymphomas: the past, the present and the future". Hematol Oncol. 19 (4): 129–50. PMID 11754390.

Template:WH Template:WS